Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with a diagnosis of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases
All consecutive patients who started Radium-223 treatment between 22 December 2014 and 01 June 2017
Availability of medical records during the observation period (22DEC2013 - 01JUN2018)
You may not be if
Patients treated with Radium-223 for any reason before 22 December 2014 (for example an interventional trial)
Patients participated in an investigational program with interventions outside of routine clinical practice during the radium-223 treatment period
Patients received other radiopharmaceuticals for the systemic concomitant use for treatment of prostate cancer or for other use during the Radium-223 treatment period
Clareo Health | A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
